{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:47:03Z","timestamp":1792860423917,"version":"4.5.0"},"reference-count":130,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.rv16003","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T17:08:06Z","timestamp":1478538486000},"page":"95-109","source":"Crossref","is-referenced-by-count":137,"title":["Postprandial Hyperlipidemia and Remnant Lipoproteins"],"prefix":"10.5551","volume":"24","author":[{"given":"Daisaku","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Rinku General Medical Center"},{"name":"Department of Community Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol. 2011; 31: 1716-1725","DOI":"10.1161\/ATVBAHA.111.226100"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Hirata A, Okamura T, Sugiyama D, Kuwabara K, Kadota A, Fujiyoshi A, Miura K, Okuda N, Ohkubo T, Okayama A, Ueshima H; NIPPON DATA90 Research Group. The Relationship between Very High Levels of Serum High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in a 20-Year Follow-Up Study of Japanese General Population. J Atheroscler Thromb. 2016; 23: 800-809","DOI":"10.5551\/jat.33449"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Klempfner R, Erez A, Sagit B-Z, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016; 9: 100-108","DOI":"10.1161\/CIRCOUTCOMES.115.002104"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, Lane MA, Erwin PJ, Berglund L, Elraiyah T, Montori VM. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012; 12: 2","DOI":"10.1186\/1472-6823-12-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. J Am Coll Cardiol. 2015; 65: 2267-2275","DOI":"10.1016\/j.jacc.2015.03.544"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K; Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 2013; 20: 517-523","DOI":"10.5551\/jat.15792"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001; 153: 490-499","DOI":"10.1093\/aje\/153.5.490"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298: 299-308","DOI":"10.1001\/jama.298.3.299"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008; 300: 2142-2152","DOI":"10.1001\/jama.2008.621"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Bor\u00e9n J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Hear J. 2016; 37: 1944-1958","DOI":"10.1093\/eurheartj\/ehw152"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Imaizumi K, Fainaru M, Havel R. Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins. J Lipid Res. 1978; 19: 712-722","DOI":"10.1016\/S0022-2275(20)41271-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mahmood Hussain M. A proposed model for the assembly of chylomicrons. Atherosclerosis. 2000; 148: 1-15","DOI":"10.1016\/S0021-9150(99)00397-4"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Fujioka Y, Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009; 16: 145-154","DOI":"10.5551\/jat.E598"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997; 38: 2173-2192","DOI":"10.1016\/S0022-2275(20)34932-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007; 117: 94-98","DOI":"10.1172\/JCI30889"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Teng BB, Ochsner S, Zhang Q, Soman K V, Lau PP, Chan L. Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1). structure-function relationships of RNA editing and dimerization. J Lipid Res. 1999; 40: 623-635","DOI":"10.1016\/S0022-2275(20)32141-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Daugherty A, Lange LG, Sobel BE, Schonfeld G. Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. J Lipid Res. 1985; 26: 955-963","DOI":"10.1016\/S0022-2275(20)34298-X"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Proctor SD, Mamo JCL. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2003; 23: 1595-1600","DOI":"10.1161\/01.ATV.0000084638.14534.0A"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Mohrschladt M, Weverling-Rijnsburger A, de Man F, Stoeken D, Sturk A, Smelt A, et al. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis. 2000; 148: 413-419","DOI":"10.1016\/S0021-9150(99)00316-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998; 18: 20-26","DOI":"10.1161\/01.ATV.18.1.20"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kawakami A, Tanaka A, Nakano T, Saniabadi A, Numano F. Stimulation of arterial smooth muscle cell proliferation by remnant lipoprotein particles isolated by immuno-affinity chromatography with anti-apo A-I and anti-apo B-100. Horm Metab Res. 2001; 33: 67-72","DOI":"10.1055\/s-2001-12397"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M. Remnant Lipoprotein-Induced Smooth Muscle Cell Proliferation Involves Epidermal Growth Factor Receptor Transactivation. Circulation. 2003; 108: 2679-2688","DOI":"10.1161\/01.CIR.0000093278.75565.87"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Zhao, D Letterman, J Schreiber B. beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell proliferation. J Biol Chem. 2001; 276: 30579-30588","DOI":"10.1074\/jbc.M103761200"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Doi H, Kugiyama K, Oka H, Sugiyama S, Ogata N, Koide SI, Nakamura SI, Yasue H. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation. 2000; 102: 670-676","DOI":"10.1161\/01.CIR.102.6.670"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kawakami A, Tanaka A, Nakajima K, Shimokado K, Yoshida M. Atorvastatin attenuates remnant lipoproteininduced monocyte adhesion to vascular endothelium under flow conditions. Circ Res. 2002; 91: 263-271","DOI":"10.1161\/01.RES.0000028454.42385.8B"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R. IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pr. 2000; 48: 127-138","DOI":"10.1016\/S0168-8227(99)00147-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther. 2005; 312: 1241-1248","DOI":"10.1124\/jpet.104.077826"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Wilhelm MG, Cooper AD. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb. 2003; 10: 132-139","DOI":"10.5551\/jat.10.132"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pitas RE, Innerarity TL, Mahley RW. Foam cells in explants of atherosclerotic rabbit aortas have receptors for beta-very low density lipoproteins and modified low density lipoproteins. Arteriosclerosis. 1983; 3: 2-12","DOI":"10.1161\/01.ATV.3.1.2"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Pal S, Semorine K, Watts GF, Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med. 2003; 41: 792-795","DOI":"10.1515\/CCLM.2003.120"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Okumura T, Fujioka Y, Morimoto S, Masai M, Sakoda T, Tsujino T, Kashiwamura S, Okamura H, Ohyanagi M. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. J Atheroscler Thromb. 2006; 13: 38-45","DOI":"10.5551\/jat.13.38"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Morimoto S, Fujioka Y, Hosoai H, Okumura T, Masai M, Sakoda T, Tsujino T, Ohyanagi M, Iwasaki T. The renin-angiotensin system is involved in the production of plasminogen activator inhibitor type 1 by cultured endothelial cells in response to chylomicron remnants. Hypertens Res. 2003; 26: 315-323","DOI":"10.1291\/hypres.26.315"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Takahashi Y, Fujioka Y, Takahashi T, Domoto K, Takahashi A, Taniguchi T, et al. Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci. 2005; 77: 670-682","DOI":"10.1016\/j.lfs.2005.01.012"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Kawasaki S, Taniguchi T, Fujioka Y, Takahashi A, Takahashi T, Domoto K, Taguchi M, Ishikawa Y, Yokoyama M. Chylomicron remnant induces apoptosis in vascular endothelial cells. Ann New York Acad Sci. 2000; 902: 336-341","DOI":"10.1111\/j.1749-6632.2000.tb06334.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kamemura, K Fujioka, Y Takaishi, H Takahashi, A Taniguchi, T Ishikawa, Y Yokoyama M. Chylomicron remnants upregulate CD40 expression via the ERK pathway and a redox-sensitive mechanism in THP-1 cells. Atherosclerosis. 2006; 187: 257-264","DOI":"10.1016\/j.atherosclerosis.2005.09.002"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Domoto K, Taniguchi T, Takaishi H, Takahashi T, Fujioka Y, Takahashi A, Ishikawa, Y Yokoyama M. Chylomicron remnants induce monocyte chemoattractant protein-1 expression via p38 MAPK activation in vascular smooth muscle cells. Atherosclerosis. 2003; 171: 193-200","DOI":"10.1016\/j.atherosclerosis.2003.08.016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Flor\u00e9n CH, Albers JJ, Bierman EL. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta. 1981; 663: 336-349","DOI":"10.1016\/0005-2760(81)90219-8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Fujioka Y, Cooper AD, Fong LG. Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages. J Lipid Res. 1998; 39: 2339-2349","DOI":"10.1016\/S0022-2275(20)33313-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Brown M, Ramprasad MP, Umeda PK, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo WL, Li R, Song R, Bradley WA, Gianturco SH. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc Natl Acad Sci USA. 2000; 97: 7488-7493","DOI":"10.1073\/pnas.120184097"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Bermudez B, Lopez S, Varela LM, Ortega A, Pacheco YM, Moreda W, Moreno-Luna R, Abia R, Muriana FJ. Triglyceride-Rich Lipoprotein Regulates APOB48 Receptor Gene Expression in Human THP-1 Monocytes and Macrophages. J Nutr. 2012; 142: 227-232","DOI":"10.3945\/jn.111.149963"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, Tanaka A, Shimokado K, Yoshida M. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through apoB48 receptordependent mechanism. Arterioscler Thromb Vasc Biol. 2005; 25: 424-429","DOI":"10.1161\/01.ATV.0000152632.48937.2d"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep. 2013; 15: 309","DOI":"10.1007\/s11883-013-0309-9"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993; 223: 53-71","DOI":"10.1016\/0009-8981(93)90062-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med. 1998; 104: 445-450","DOI":"10.1016\/S0002-9343(98)00089-8"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46) Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N, Kurimoto Y, Yamada S, Ishikawa Y. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care. 1999; 22: 152-156","DOI":"10.2337\/diacare.22.1.152"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb. 2004; 11: 322-329","DOI":"10.5551\/jat.11.322"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Ai M, Tanaka A, Ogita K, Sekinc M, Numano FF, Numano FF, Reaven GM. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol. 2001; 38: 1628-1632","DOI":"10.1016\/S0735-1097(01)01611-4"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Funada JI, Sekiya M, Otani T, Watanabe K, Sato M, Akutsu H. The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis. 2004; 172: 151-154","DOI":"10.1016\/j.atherosclerosis.2003.09.016"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Lemieux I, Couillard C, Pascot A, Bergeron N, Prud\u2019homme D, Bergeron J, et al. The small, dense LDL phenotype as a correlate of postprandial lipemia in men. Atherosclerosis. 2000; 153: 423-432","DOI":"10.1016\/S0021-9150(00)00424-X"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51) Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014; 141: 358-367","DOI":"10.1016\/j.pharmthera.2013.11.008"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52) Okazaki M, Usui S, Fukui A, Kubota I, Tomoike H. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem. 2006; 52: 2049-2053","DOI":"10.1373\/clinchem.2006.070094"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53) St-Pierre AC, Cantin B, Dagenais GR, Mauri\u00e8ge P, Bernard PM, Despr\u00e9s JP, Lamarche B. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005; 25: 553-559","DOI":"10.1161\/01.ATV.0000154144.73236.f4"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54) Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000; 20: 2140-2147","DOI":"10.1161\/01.ATV.20.9.2140"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55) Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intimamedia thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res. 2001; 42: 17-21","DOI":"10.1016\/S0022-2275(20)32331-2"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56) Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K, Curb JD. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu heart study. Arterioscler Thromb Vasc Biol. 2005; 25: 1718-1722","DOI":"10.1161\/01.ATV.0000173310.85845.7b"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57) Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, Tsunoda R, Sakamoto T, Nakano T, Nakajima K, Ogawa H, Sugiyama S, Yoshimura M, Yasue H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 1999; 99: 2858-2860","DOI":"10.1161\/01.CIR.99.22.2858"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58) Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem. 2007; 53: 2128-2135","DOI":"10.1373\/clinchem.2007.092296"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59) Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceriderich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992; 33: 369-380","DOI":"10.1016\/S0022-2275(20)41527-5"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60) Nakada Y, Kurosawa H, Tohyama J-I, Inoue Y, Ikewaki K. Increased Remnant Lipoprotein in Patients with Coronary Artery Disease\u2013Evaluation Utilizing a Newly Developed Remnant Assay, Remnant Lipoproteins Cholesterol Homogenous Assay (RemL-C). J Atheroscler Thromb. 2007; 14: 56-64","DOI":"10.5551\/jat.14.56"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61) Yoshida H, Kurosawa H, Hirowatari Y, Ogura Y, Ikewaki K, Abe I, Saikawa S, Domitsu K, Ito K, Yanai H, Tada N. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C). Lipids Health Dis. 2008; 7: 18","DOI":"10.1186\/1476-511X-7-18"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62) Sonoda M, Shoji T, Kimoto E, Okute Y, Shima H, Naganuma T, Motoyama K, Morioka T, Mori K, Fukumoto S, Shioi A, Koyama H, Emoto M, Inaba M.. Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus. J Atheroscler Thromb. 2014; 21: 346-354","DOI":"10.5551\/jat.20594"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63) Matsuo N, Matsuoka T, Onishi S, Yamamoto H, Kato A, Makino Y, Kihara S. Impact of Remnant Lipoprotein on Coronary Plaque Components. J Atheroscler Thromb. 2015; 22: 783-795","DOI":"10.5551\/jat.26328"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64) Taguchi M, Ishigami M, Nishida M, Moriyama T, Yamashita S, Yamamura T. Remnant lipoprotein-cholesterol is a predictive biomarker for large artery atherosclerosis in apparently healthy women: usefulness as a parameter for annual health examinations. Ann Clin Biochem. 2011; 48: 332-327","DOI":"10.1258\/acb.2011.010244"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65) Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979; 60: 473-485","DOI":"10.1161\/01.CIR.60.3.473"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66) Karpe F, Hell\u00e9nius ML, Hamsten A. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolism. 1999; 48: 301-307","DOI":"10.1016\/S0026-0495(99)90076-8"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67) Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med. 1999; 246: 341-355","DOI":"10.1046\/j.1365-2796.1999.00548.x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol. 1999; 19: 2474-2486","DOI":"10.1161\/01.ATV.19.10.2474"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Uchida Y, Kurano Y, Ito S. Establishment of monoclonal antibody against human Apo B-48 and measurement of Apo B-48 in serum by ELISA method. J Clin Lab Anal. 1998; 12: 289-292","DOI":"10.1002\/(SICI)1098-2825(1998)12:5<289::AID-JCLA7>3.0.CO;2-1"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y, Kihara S, Hiraoka H, Nakamura T, Ito S, Yamashita S, Matsuzawa Y. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res. 2003; 44: 1256-1262","DOI":"10.1194\/jlr.M300090-JLR200"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) Hanada H, Mugii S, Okubo M, Maeda I, Kuwayama K, Hidaka Y, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Nakatani K, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Nishida M, Komuro I, Yamashita S. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clin Chim Acta. 2012; 413: 160-165","DOI":"10.1016\/j.cca.2011.09.013"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Masuda D, Nishida M, Arai T, Hanada H, Yoshida H, Yamauchi-Takihara K, Moriyama T, Tada N, Yamashita S.. Reference Interval for the Apolipoprotein B-48 Concentration in Healthy Japanese Individuals. J Atheroscler Thromb. 2014; 21: 618-627","DOI":"10.5551\/jat.22558"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M, Ishigami M, Masuda Y, Matsuyama A, Komuro I, Yamashita S. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb. 2011; 18: 1062-1070","DOI":"10.5551\/jat.10470"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74) Kinoshita M, Ohnishi H, Maeda T, Yoshimura N, Takeoka Y, Yasuda D, Kusano J, Mashimo Y, Saito S, Shimamoto K, Teramoto T. Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome. J Atheroscler Thromb. 2009; 16: 517-522","DOI":"10.5551\/jat.No604"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) Yuasa-Kawase M, Masuda D, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Tsubakio-Yamamoto K, Ohama T, Toyama-Nakagawa Y, Nishida M, Ishigami M, Saito M, Eto M, Matsuyama A, Komuro I, Yamashita S. Apolipoprotein B-48 to triglyceride ratio is a novel and useful marker for detection of type III hyperlipidemia after antihyperlipidemic intervention. J Atheroscler Thromb. 2012; 19: 862-871","DOI":"10.5551\/jat.13052"},{"key":"75","unstructured":"76) Mugii S, Hanada H, Takeoka K, Hidaka Y, Masuda D, Ohama T, Toyama Y, Yamashita S. Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease. Rinsho Byori. 2009; 57: 1058-1063"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77) Okubo M, Hanada H, Matsui M, Hidaka Y, Masuda D, Sakata Y, Yamashita S. Serum apolipoprotein B-48 concentration is associated with a reduced estimated glomerular filtration rate and increased proteinuria. J Atheroscler Thromb. 2014; 21: 974-982","DOI":"10.5551\/jat.23309"},{"key":"77","doi-asserted-by":"crossref","unstructured":"78) Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M. Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008; 197: 154-158","DOI":"10.1016\/j.atherosclerosis.2007.03.015"},{"key":"78","doi-asserted-by":"crossref","unstructured":"79) Guo Q, Avramoglu RK, Adeli K, Kohen Avramoglu R, Adeli K. Intestinal assembly and secretion of highly dense\/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metabolism. 2005; 54: 689-697","DOI":"10.1016\/j.metabol.2004.12.014"},{"key":"79","doi-asserted-by":"crossref","unstructured":"80) Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 2002; 277: 31646-31655","DOI":"10.1074\/jbc.M200544200"},{"key":"80","doi-asserted-by":"crossref","unstructured":"81) Nakatani K, Sugimoto T, Masuda D, Okano R, Oya T, Monden Y, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Komuro I, Yamashita S. Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels. Atherosclerosis. 2011; 218: 226-232","DOI":"10.1016\/j.atherosclerosis.2011.05.009"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82) Masuda D, Sugimoto T, Tsujii K-I, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I, Yamashita S.. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest. 2012; 42: 992-999","DOI":"10.1111\/j.1365-2362.2012.02687.x"},{"key":"82","doi-asserted-by":"crossref","unstructured":"83) Mori K, Ishida T, Yasuda T, Monguchi T, Sasaki M, Kondo K, Hasokawa M, Nakajima H, Haraguchi Y, Sun L, Shinohara M, Toh R, Nishimura K, Hirata K. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin Chim Acta. 2013; 421: 51-56","DOI":"10.1016\/j.cca.2013.02.005"},{"key":"83","doi-asserted-by":"crossref","unstructured":"84) Cara L, Dubois C, Borel P, Armand M, Senft M, Portugal H, Pauli AM, Bernard PM, Lairon D. Effects of oat bran, rice bran, wheat fiber, and wheat germ on postprandial lipemia in healthy adults. Am J Clin Nutr. 1992; 55: 81-88","DOI":"10.1093\/ajcn\/55.1.81"},{"key":"84","doi-asserted-by":"crossref","unstructured":"85) Annuzzi G, Bozzetto L, Costabile G, Giacco R, Mangione A, Anniballi G, Vitale M, Vetrani C, Cipriano P, Della Corte G, Pasanisi F, Riccardi G, Rivellese AA.. Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial. Am J Clin Nutr. 2014; 99: 463-471","DOI":"10.3945\/ajcn.113.073445"},{"key":"85","doi-asserted-by":"crossref","unstructured":"86) Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr. 2012; 95: 740-751","DOI":"10.3945\/ajcn.111.023457"},{"key":"86","doi-asserted-by":"crossref","unstructured":"87) Aoyama T, Nosaka N, Kasai M. Research on the nutritional characteristics of medium-chain fatty acids. J Med Invest. 2007; 54: 385-388","DOI":"10.2152\/jmi.54.385"},{"key":"87","doi-asserted-by":"crossref","unstructured":"88) Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. Diacylglycerol oil for the metabolic syndrome. Nutr J.2007; 6: 43","DOI":"10.1186\/1475-2891-6-43"},{"key":"88","doi-asserted-by":"crossref","unstructured":"89) Maki KC, Mustad V, Dicklin MR, Geohas J. Postprandial metabolism with 1,3-diacylglycerol oil versus equivalent intakes of long-chain and medium-chain triacylglycerol oils. Nutrition. 2009; 25: 627-633","DOI":"10.1016\/j.nut.2008.11.028"},{"key":"89","doi-asserted-by":"crossref","unstructured":"90) Takase H, Shoji K, Hase T, Tokimitsu I. Effect of diacylglycerol on postprandial lipid metabolism in non-diabetic subjects with and without insulin resistance. Atherosclerosis. 2005; 180: 197-204","DOI":"10.1016\/j.atherosclerosis.2004.11.020"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91) Yasunaga K, Saito S, Zhang Y, Hernandez-Ono A, Ginsberg HN. Effects of triacylglycerol and diacylglycerol oils on blood clearance, tissue uptake, and hepatic apolipoprotein B secretion in mice. J Lipid Res. 2007; 48: 1108-1121","DOI":"10.1194\/jlr.M600524-JLR200"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92) Nagao T, Watanabe H, Goto N, Onizawa K, Taguchi H, Matsuo N, Yasukawa T, Tsushima R, Shimasaki H, Itakura H. Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial. J Nutr. 2000; 130: 792-797","DOI":"10.1093\/jn\/130.4.792"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93) Fujii A, Allen TJ, Nestel PJ. A 1,3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice. Atherosclerosis. 2007; 193: 55-61","DOI":"10.1016\/j.atherosclerosis.2006.08.024"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94) Ooi EM, Lichtenstein AH, Millar JS, Diffenderfer MR, Lamon-Fava S, Rasmussen H, Welty FK, Barrett PH, Schaefer EJ. Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J Lipid Res. 2012; 53: 1958-1967","DOI":"10.1194\/jlr.P024315"},{"key":"94","doi-asserted-by":"crossref","unstructured":"95) Ooi EMM, Watts GF, Ng TWK, Barrett PHR. Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients. 2015; 7: 4416-4425","DOI":"10.3390\/nu7064416"},{"key":"95","doi-asserted-by":"crossref","unstructured":"96) Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988; 82: 1884-1893","DOI":"10.1172\/JCI113806"},{"key":"96","doi-asserted-by":"crossref","unstructured":"97) Miyoshi T, Noda Y, Ohno Y, Sugiyama H, Oe H, Nakamura K, Kohno K, Ito H. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial. Biomed Pharmacother. 2014; 68: 1071-1077","DOI":"10.1016\/j.biopha.2014.10.008"},{"key":"97","doi-asserted-by":"crossref","unstructured":"98) Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009; 73: 1283-1290","DOI":"10.1253\/circj.CJ-08-1197"},{"key":"98","doi-asserted-by":"crossref","unstructured":"99) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"99","doi-asserted-by":"crossref","unstructured":"100) Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200: 135- 140","DOI":"10.1016\/j.atherosclerosis.2008.06.003"},{"key":"100","doi-asserted-by":"crossref","unstructured":"101) Purcell R, Latham SH, Botham KHM, Hall WL, Wheeler-Jones CPD. High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2\u03b1 concentrations relative to a control high-oleic acid meal: A randomized controlled trial. Am J Clin Nutr. 2014; 100: 1019-1028","DOI":"10.3945\/ajcn.114.091223"},{"key":"101","doi-asserted-by":"crossref","unstructured":"103) Parhofer KG, Laubach E, Barrett PHR. Effect of atorvastatin on postprandial lipoprotein metabolism in hyper-triglyceridemic patients. J Lipid Res. 2003; 44: 1192-1198","DOI":"10.1194\/jlr.M300011-JLR200"},{"key":"102","doi-asserted-by":"crossref","unstructured":"104) Nagashima H, Endo M. Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels. 2011; 26: 428-434","DOI":"10.1007\/s00380-010-0071-7"},{"key":"103","doi-asserted-by":"crossref","unstructured":"105) Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, Kawakami M, Momomura S. Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J. 2009; 73: 1523-1530","DOI":"10.1253\/circj.CJ-08-0917"},{"key":"104","doi-asserted-by":"crossref","unstructured":"106) Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007; 30: 1945-1951","DOI":"10.2337\/dc07-0015"},{"key":"105","doi-asserted-by":"crossref","unstructured":"107) Sabine W, Lilli W, Katrin G, Jutta D, Claus L. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis. 2003; 171: 369-377","DOI":"10.1016\/j.atherosclerosis.2003.08.030"},{"key":"106","doi-asserted-by":"crossref","unstructured":"108) Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Komuro I, Yamashita S. Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. J Atheroscler Thromb. 2010; 17: 610-618","DOI":"10.5551\/jat.3988"},{"key":"107","doi-asserted-by":"crossref","unstructured":"109) Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M, Yamashita Y, Takada M, Tsubakio-Yamamoto K, Tochino Y, Koseki M, Matsuura F, Nishida M, Kawamoto T, Ishigami M, Hori M, Shimomura I, Yamashita S.. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res. 2009; 50: 999-1011","DOI":"10.1194\/jlr.P700032-JLR200"},{"key":"108","doi-asserted-by":"crossref","unstructured":"110) Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, Fisman EZ, Tenenbaum A; BIP Study Group. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. Cardiovasc Diabetol. 2016; 15: 11","DOI":"10.1186\/s12933-016-0332-6"},{"key":"109","doi-asserted-by":"crossref","unstructured":"111) Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d&apos;Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849-1861","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"110","doi-asserted-by":"crossref","unstructured":"112) ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"},{"key":"111","doi-asserted-by":"crossref","unstructured":"114) Hajer GR, Dallinga-Thie GM, van Vark - van der Zee LC, Visseren FLJ. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis. 2009; 202: 216-224","DOI":"10.1016\/j.atherosclerosis.2008.04.035"},{"key":"112","doi-asserted-by":"crossref","unstructured":"115) Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Matsuyama A, Nishida M, Ishigami M, Komuro I, Yamashita S. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb. 2010; 17: 914-924","DOI":"10.5551\/jat.4929"},{"key":"113","doi-asserted-by":"crossref","unstructured":"116) Westerink J, Deanfield JE, Imholz BP, Spiering W, Basart DC, Coll B, Kastelein JJ, Visseren FL. High-dose statin monotherapy versus low-dose statin\/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis. 2013; 227: 118-124","DOI":"10.1016\/j.atherosclerosis.2012.11.028"},{"key":"114","doi-asserted-by":"crossref","unstructured":"117) Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 2011; 217: 486-491","DOI":"10.1016\/j.atherosclerosis.2011.04.019"},{"key":"115","doi-asserted-by":"crossref","unstructured":"118) Kikuchi K, Nezu U, Inazumi K, Miyazaki T, Ono K, Shirakawa J, Sato K, Koike H, Wakasugi T, Sato M, Kawakami C, Watanabe S, Yamakawa T, Terauchi Y. Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb. 2012; 19: 1093-1101","DOI":"10.5551\/jat.12427"},{"key":"116","doi-asserted-by":"crossref","unstructured":"119) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"117","doi-asserted-by":"crossref","unstructured":"120) Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13: 366-373","DOI":"10.1111\/j.1463-1326.2011.01362.x"},{"key":"118","doi-asserted-by":"crossref","unstructured":"121) Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94: 846-852","DOI":"10.1210\/jc.2008-1400"},{"key":"119","doi-asserted-by":"crossref","unstructured":"122) Matikainen N, M\u00e4ntt\u00e4ri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006; 49: 2049-2057","DOI":"10.1007\/s00125-006-0340-2"},{"key":"120","doi-asserted-by":"crossref","unstructured":"123) Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010; 53: 552-561","DOI":"10.1007\/s00125-009-1611-5"},{"key":"121","doi-asserted-by":"crossref","unstructured":"124) Hermansen K, B\u00e6kdal TA, D\u00fcring M, Pietraszek A, Mortensen LS, J\u00f8rgensen H, Flint A. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013; 15: 1040-1048","DOI":"10.1111\/dom.12133"},{"key":"122","doi-asserted-by":"crossref","unstructured":"125) Meier JJ, Gethmann A, G\u00f6tze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006; 49: 452-458","DOI":"10.1007\/s00125-005-0126-y"},{"key":"123","doi-asserted-by":"crossref","unstructured":"126) Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-1326","DOI":"10.1056\/NEJMoa1307684"},{"key":"124","doi-asserted-by":"crossref","unstructured":"127) White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-1335","DOI":"10.1056\/NEJMoa1305889"},{"key":"125","doi-asserted-by":"crossref","unstructured":"128) Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-242","DOI":"10.1056\/NEJMoa1501352"},{"key":"126","doi-asserted-by":"crossref","unstructured":"129) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375: 311-322","DOI":"10.1056\/NEJMoa1603827"},{"key":"127","doi-asserted-by":"crossref","unstructured":"130) Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, doubleblind, parallel-group comparative study. Cardiovasc Diabetol. 2014; 13: 65","DOI":"10.1186\/1475-2840-13-65"},{"key":"128","doi-asserted-by":"crossref","unstructured":"131) Ji L, Ma J, Li H, Mansfield TA, T\u2019joen CL, Iqbal N, Ptaszynska A, List JF. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36: 84-100","DOI":"10.1016\/j.clinthera.2013.11.002"},{"key":"129","doi-asserted-by":"crossref","unstructured":"132) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-2128","DOI":"10.1056\/NEJMoa1504720"},{"key":"130","doi-asserted-by":"crossref","unstructured":"133) Yoshimura N, Kinoshita M, Teramoto T. Isolation and characterization of apolipoprotein B48-containing lipoproteins with a monoclonal antibody against apolipoprotein B48. J Atheroscler Thromb. 2009; 16: 740-747","DOI":"10.5551\/jat.No976"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_RV16003\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:51:29Z","timestamp":1657633889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_RV16003\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":130,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv16003","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}